BullFrog AI Holdings, Inc. ( (BFRG) ) has issued an update.
Bullfrog AI Holdings, Inc. has released promising research data for its liver disease treatment candidate, BF-114, which targets the protein β2-spectrin and shows potential in preventing disease progression. Published in Cell Reports and led by renowned liver disease expert Dr. Lopa Mishra, the study supports the therapeutic prospects of BF-114 in treating obesity-related liver conditions, including MASLD, MASH, and HCC. As Bullfrog AI integrates artificial intelligence into drug development, Dr. Mishra’s addition to their Scientific Advisory Board is set to further advance their BF-114 program.
For detailed information about BFRG stock, go to TipRanks’ Stock Analysis page.
